AZN AstraZeneca PLC

By Anthony O. Goriainoff

AstraZeneca PLC said Wednesday that Lynparza has been approved in the U.S. for use in patients with prostate cancer.

The London-listed drugmaker said the U.S. Food and Drug Administration approved the drug based on results from the phase 3 PROfound trial , which were published in the New England Journal of Medicine.

The company said that following the approval it will receive a regulatory milestone payment from MSD Research Laboratories of $35 million, and that this will be booked as collaboration revenue during the second quarter of 2020.

The company said Lynparza is currently under regulatory review in the European Union and other jurisdictions as a treatment for men with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

May 20, 2020 02:31 ET (06:31 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.